CellCeutix pharmaceutical company

We have acquired exclusive rights to several drugs against a number of human diseases. Our current portfolio of product candidates in pre-clinical development include two anti-cancer agents targeting four different tumors (Kevetrin and KM362); one candidate targeting rheumatoid arthritis (KM277); a small molecule compound with an indication of osteo-arthritis/asthma (KM278); a small molecule compound with an indication of neurological disorders for the treatment of Multiple Sclerosis, Lou Gherig Disease, and/or Parkinson's Disease (KM-3174) and a small molecule compound for the treatment of Psoriasis (KM133). 

A New Compound is Being Developed For The Treatment Of Head And Neck Cancers.

Kevetrin, our lead product candidate, is a small molecule compound proprietary to the Company initially being developed to treat head and neck cancers. There is a potential for use of Kevetrin in multiple tumor types. Kevetrin was discovered by the Company’s founder, Dr. Krishna Menon. Kevetrin has been studied extensively in in-vitro and in-vivo studies on over 5000 animals of various species. Kevetrin's mechanism of action is through multiple biological pathways as an alkalating agent and LTB4 inhibitor with anti-angiogenic properties. Since the compound works through MMOA, “Multiple Mechanisms of Action”, a single compound can attack the progress of cancer through multiple biological pathways, as well as may have a positive impact on other diseases. These “Multiple Mechanism of Actions” may have a better potential to attack the cancer cells through multiple pathways that affect the multiplication and formation of the cancer cells along with interruption of the formation of new blood vessels that supply vital nutrients to tumor cells and sustain the tumor growth.

In-vivo studies on over 1000 animal subjects have been conducted to check for efficacy of the compound in rhumatoid arthritis. Related in vitro assays including ex-vivo studies have resulted in the Company’s management to believe that the compound has developmental potential for the treatment of the disease

This compound showed efficacy in both Osteo-arthritis animal models and Asthma models in animals. We tested the compounds against standard treatment against both asthma and Osteo-arthritis and based on the data. These studies have resulted in the Company’s management to believe that the compound has developmental potential for the treatment of the diseases

A small molecule, acting on the principles of folate mechanism, was found to be effective against Psoriasis, both in induced psoriasis in animals as well as xenograft models with human psoriatic tissue. We have tested the compound both in vitro and in vivo. These studies have resulted in the Company’s management to believe that the compound has developmental potential for the treatment of the diseases.

Amylation is a character in most neurological diseases, where there is no treatment at all, as in case of Lou Gherig Disease, Parkinson’s Disease and Multiple Sclerosis, etc. Initial study results are conclusive of the compounds ability to target all of these neurological diseases. These early studies indicate this compound aids in demylation along with strengthening the functions of the nerves, spinal chord and the brain tissue.

This is a very early stage developmental compound in the treatment of cancer. After additional in vitro and in vivo studies the Company will determine whether to advance this compound for further development.